Each Baqsimi device includes 1 dose of glucagon and cannot be refused. The Food and Drug Administration (FDA) has expanded the approval of Baqsimi (glucagon) nasal powder to include the treatment of ...

The global nasal packing devices market is poised for substantial growth over the next decade, with experts projecting a steady upward trajectory driven by increasing medical needs and innovation in ...

Wearable Furosemide Delivery System Approved for CKD Patients Baqsimi (glucagon nasal powder) Antihypoglycemic Treatment of severe hypoglycemia in patients aged 1 year and older with diabetes.

Researchers at Columbus-based Ohio State University have designed and developed the world’s first noninvasive devices aimed ...

A key contributor to the steady growth in the rhinoscope devices market is the increasing prevalence of nasal disorders, conditions that impact the nose and affect breathing, smell or sinus ...

Baqsimi is a nasal spray formulation of glucagon, already widely used as an injectable treatment for hypoglycaemia, which can occur when people with diabetes inadvertently take too much insulin.

Researchers at Ohio State University have announced they are the first in the world to test new non-invasive devices.

Significantly more patients with acute migraine who received a 10 L per minute dose of a transnasal cooling device had pain freedom at 2 hours vs. those who received sham, according to research ...

We have an update on the One UI 7 rollout and it’s good news this time – the press release from Samsung Singapore lists more devices that will be updated to the latest Samsung software.

Geoffrey Seiler has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends Advanced Micro Devices, Amazon, and Nvidia. The Motley Fool has a disclosure policy.